A lipid-modified platinum-derivative-based nanoparticle delivery system for survivin siRNA in combination with cisplatin exhibited improved therapeutic efficacy in chemo-resistant LC model, suggesting that RNA therapeutics against survivin is a promising approach [296]. This evidence concerns the gene BIRC5 and laryngotracheoesophageal cleft.